JWK010

JWK010 is an investigational gene therapy being developed by West China Hospital of Sichuan University for the treatment of oculocutaneous albinism type 1 (OCA1). OCA1 is a genetic disorder caused by mutations in the *TYR* gene, which encodes the enzyme tyrosinase, essential for the production of melanin pigment. JWK010 is designed to deliver a functional copy of the *TYR* gene to ocular tissues via suprachoroidal injection. This delivery method is intended to target the retinal pigment epithelium and other posterior segment structures to restore tyrosinase activity and melanin production, potentially improving visual function and retinal development in affected individuals. The therapy is currently being evaluated in a single-arm interventional study involving pediatric subjects to assess its safety, tolerability, and effects on visual function and retinal structure.